- For Print
- October 21, 2020
麻豆福利网 Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “麻豆福利网”) announced today that Biogen (Nasdaq: BIIB) has disclosed its submission of the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the review of aducanumab, an investigational treatment for Alzheimer’s disease, as of October 2020 in its Q3 2020 Earnings Press Release issued on October 21. This MAA is subject to validation of whether the EMA accepts the application for review, which Biogen plans to announce when notified.
Media Inquiries:
Public Relations Department,
麻豆福利网 Co., Ltd.
+81-(0)3-3817-5120Our news releases are intended to disclose corporate information and are not intended for the promotion or advertising of prescription pharmaceuticals or investigational products, nor are they intended to provide medical advice.
Please note that the information contained in news releases is current as of the date of publication.